This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Current FDA-Related Drug Information 
Elvitegravir -Vitekta (Gilead)
Comparative agents:
Original part of a 4-drug combination product (Stribild)
Indication: Treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.
Mechanism of action:
HIV-1 integrase strand transfer inhibitor 
Indication:
Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy
Mechanism of action:
Palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. Current FDA-Related Drug Information CONTRAINDICATIONS Glaucoma: Ozurdex is contraindicated in patients with glaucoma, who have cup to disc ratios of greater than 0.8. Torn or Ruptured Posterior Lens Capsule: Ozurdex is contraindicated in patients whose posterior lens capsule is torn or ruptured because of the risk of migration into the anterior chamber. Laser posterior capsulotomy in pseudophakic patients is not a contraindication for Ozurdex use. Hypersensitivity: Ozurdex is contraindicated in patients with known hypersensitivity to any components of this product. WARNINGS AND PRECAUTIONS Steroid-related Effects: Corticosteroids are not recommended to be used in patients with a history of ocular herpes simplex because of the potential for reactivation of the viral infection. ADVERSE REACTIONS Clinical Studies Experience: Revised to include revised intraocular pressure data and adverse reaction data for the diabetic macular edema indication. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm295117.htm • Patients receiving the combination of losartan and lisinopril did not obtain any additional benefi t compared to monotherapy for the combined endpoint of decline in glomerular fi ltration rate (GFR), end-stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. Closely monitor blood pressure, renal function, and electrolytes in patients on Hyzaar and other agents that affect the RAS. Drug Interactions, Hydrochlorothiazide -Lithium: Should not generally be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Monitor serum lithium levels during concomitant use. Refer to the package insert for lithium preparations before use of such preparations with Hyzaar. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm169677.htm
Peginterferon alfa-2a
Pegasys (Genentech) Ribavirin information removed from Boxed Warning. New contraindications: All contraindications of other drugs used in the treatment of hepatitis C apply to combination therapy with peginterferon alfa-2a; ribavirin is contraindicated in pregnant women and men whose female partners are pregnant. Warnings and Precautions: Warnings and precautions related to the other drugs used in the treatment of hepatitis C apply to combination therapy with peginterferon alfa-2a. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm247047.htm (CONT.) (continued) Current FDA-Related Drug Information 
WARNINGS AND PRECAUTIONS: Neoplasms
• In childhood cancer survivors who were treated with radiation to the brain/ head for their fi rst neoplasm and who developed subsequent growth hormone defi ciency (GHD) and were treated with somatropin, an increased risk of a second neoplasm has been reported. Intracranial tumors, in particular meningiomas, were the most common of these second neoplasms. In adults, it is unknown whether there is any relationship between somatropin replacement therapy and CNS tumor recurrence. • Monitor all patients with a history of GHD secondary to an intracranial neoplasm routinely while on somatropin therapy for progression or recurrence of the tumor. Because children with certain rare genetic causes of short stature have an increased risk of developing malignancies, practitioners should thoroughly consider the risks and benefi ts of starting somatropin in these patients. 
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